Cargando…
Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
RATIONALE: Patients with combined pulmonary fibrosis and emphysema (CPFE) may develop acute exacerbations of IPF (AE-IPF) or COPD (AE-COPD). The incidence and the characteristics of exacerbations in patients with CPFE (e.g., COPD vs IPF) have not been well described. OBJECTIVES: To compare the incid...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325151/ https://www.ncbi.nlm.nih.gov/pubmed/32605574 http://dx.doi.org/10.1186/s12931-020-01432-x |
_version_ | 1783552097978941440 |
---|---|
author | Zantah, Massa Dotan, Yaniv Dass, Chandra Zhao, Hauqing Marchetti, Nathaniel Criner, Gerard J. |
author_facet | Zantah, Massa Dotan, Yaniv Dass, Chandra Zhao, Hauqing Marchetti, Nathaniel Criner, Gerard J. |
author_sort | Zantah, Massa |
collection | PubMed |
description | RATIONALE: Patients with combined pulmonary fibrosis and emphysema (CPFE) may develop acute exacerbations of IPF (AE-IPF) or COPD (AE-COPD). The incidence and the characteristics of exacerbations in patients with CPFE (e.g., COPD vs IPF) have not been well described. OBJECTIVES: To compare the incidence and rate of exacerbations in patients with CPFE vs. IPF and evaluate their effect on clinical outcomes. METHODS: Comprehensive clinical data from CPFE and IPF patients were retrospectively reviewed. Baseline characteristics including lung function data, oxygen requirements, and pulmonary hemodynamics, were collected. Acute exacerbation events in both groups were defined clinically and radiographically. In the CPFE group, two patterns of exacerbations were identified. AE-COPD was defined clinically by symptoms of severe airflow obstruction causing respiratory failure and requiring hospitalization. Radiographic data were also defined based on previously published literature. AE-IPF was defined clinically as an acute hypoxic respiratory failure, requiring hospitalization and treatment with high dose corticosteroids. Radiographically, patients had to have a change in baseline imaging including presence of ground-glass opacities, interlobular septal thickening or new consolidations; that is not fully explained by other etiologies. RESULTS: Eighty-five CPFE patients were retrospectively compared to 112 IPF patients. Of 112 patients with IPF; 45 had AE-IPF preceding lung transplant (40.18%) compared to 12 patients in the CPFE group (14.1%) (p < 0.05). 10 patients in the CPFE group experienced AE-COPD (11.7%). Patients with AE-IPF had higher mortality and more likely required mechanical ventilation and extracorporeal membrane oxygenation (ECMO) compared to patients with AE-COPD, whether their underlying disease was IPF or CPFE. CONCLUSIONS: CPFE patients may experience either AE-IPF or AE-COPD. Patients with CPFE and AE-COPD had better outcomes, requiring less intensive therapy compared to patients with AE-IPF regardless if underlying CPFE or IPF was present. These data suggest that the type of acute exacerbation, AE-COPD vs AE-IPF, has important implications for the treatment and prognosis of patients with CPFE. |
format | Online Article Text |
id | pubmed-7325151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73251512020-06-30 Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema Zantah, Massa Dotan, Yaniv Dass, Chandra Zhao, Hauqing Marchetti, Nathaniel Criner, Gerard J. Respir Res Research RATIONALE: Patients with combined pulmonary fibrosis and emphysema (CPFE) may develop acute exacerbations of IPF (AE-IPF) or COPD (AE-COPD). The incidence and the characteristics of exacerbations in patients with CPFE (e.g., COPD vs IPF) have not been well described. OBJECTIVES: To compare the incidence and rate of exacerbations in patients with CPFE vs. IPF and evaluate their effect on clinical outcomes. METHODS: Comprehensive clinical data from CPFE and IPF patients were retrospectively reviewed. Baseline characteristics including lung function data, oxygen requirements, and pulmonary hemodynamics, were collected. Acute exacerbation events in both groups were defined clinically and radiographically. In the CPFE group, two patterns of exacerbations were identified. AE-COPD was defined clinically by symptoms of severe airflow obstruction causing respiratory failure and requiring hospitalization. Radiographic data were also defined based on previously published literature. AE-IPF was defined clinically as an acute hypoxic respiratory failure, requiring hospitalization and treatment with high dose corticosteroids. Radiographically, patients had to have a change in baseline imaging including presence of ground-glass opacities, interlobular septal thickening or new consolidations; that is not fully explained by other etiologies. RESULTS: Eighty-five CPFE patients were retrospectively compared to 112 IPF patients. Of 112 patients with IPF; 45 had AE-IPF preceding lung transplant (40.18%) compared to 12 patients in the CPFE group (14.1%) (p < 0.05). 10 patients in the CPFE group experienced AE-COPD (11.7%). Patients with AE-IPF had higher mortality and more likely required mechanical ventilation and extracorporeal membrane oxygenation (ECMO) compared to patients with AE-COPD, whether their underlying disease was IPF or CPFE. CONCLUSIONS: CPFE patients may experience either AE-IPF or AE-COPD. Patients with CPFE and AE-COPD had better outcomes, requiring less intensive therapy compared to patients with AE-IPF regardless if underlying CPFE or IPF was present. These data suggest that the type of acute exacerbation, AE-COPD vs AE-IPF, has important implications for the treatment and prognosis of patients with CPFE. BioMed Central 2020-06-30 2020 /pmc/articles/PMC7325151/ /pubmed/32605574 http://dx.doi.org/10.1186/s12931-020-01432-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zantah, Massa Dotan, Yaniv Dass, Chandra Zhao, Hauqing Marchetti, Nathaniel Criner, Gerard J. Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema |
title | Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema |
title_full | Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema |
title_fullStr | Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema |
title_full_unstemmed | Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema |
title_short | Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema |
title_sort | acute exacerbations of copd versus ipf in patients with combined pulmonary fibrosis and emphysema |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325151/ https://www.ncbi.nlm.nih.gov/pubmed/32605574 http://dx.doi.org/10.1186/s12931-020-01432-x |
work_keys_str_mv | AT zantahmassa acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema AT dotanyaniv acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema AT dasschandra acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema AT zhaohauqing acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema AT marchettinathaniel acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema AT crinergerardj acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema |